Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
Clin Cardiol ; 33(2): 104-10, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20186992

ABSTRACT

BACKGROUND: The hypertrophic myocardium, myocardial fiber disarray, and endocardial fibroelastosis in pulmonary atresia and intact ventricular septum (PAIVS) may provide anatomic substrates for restrictive filling of the right ventricle. HYPOTHESIS: Restrictive right ventricle (RV) physiology is related to RV fibrosis and exercise capacity in patients after biventricular repair of PAIVS. METHODS: A total of 27 patients, age 16.5 +/- 5.6 years, were recruited after biventricular repair of PAIVS. Restrictive RV physiology was defined by the presence of antegrade diastolic pulmonary flow and RV fibrosis assessed by late gadolinium enhancement (LGE) cardiac magnetic resonance. Their RV function was compared with that of 27 healthy controls and related to RV LGE score and exercise capacity. RESULTS: Compared with controls, PAIVS patients had lower tricuspid annular systolic and early diastolic velocities, RV global longitudinal systolic strain, systolic strain rate, and early and late diastolic strain rates (all P < 0.05). A total of 22 (81%, 95% confidence interval: 62%-94%) PAIVS patients demonstrated restrictive RV physiology. Compared to those without restrictive RV physiology (n = 5), these 22 patients had lower RV global systolic strain, lower RV systolic and early diastolic strain rates, higher RV LGE score, and a greater percent of predicted maximum oxygen consumption (all P < 0.05). CONCLUSION: Restrictive RV physiology reflects RV diastolic dysfunction and is associated with more severe RV fibrosis but better exercise capacity in patients after biventricular repair of PAIVS.


Subject(s)
Cardiac Surgical Procedures , Cardiomyopathy, Restrictive/diagnosis , Exercise Test , Exercise Tolerance , Magnetic Resonance Imaging , Pulmonary Atresia/surgery , Ventricular Dysfunction, Right/diagnosis , Ventricular Function, Right , Adolescent , Cardiac Surgical Procedures/adverse effects , Cardiomyopathy, Restrictive/etiology , Cardiomyopathy, Restrictive/physiopathology , Case-Control Studies , Catheterization , Contrast Media , Echocardiography, Doppler , Female , Fibrosis , Gadolinium DTPA , Heart Ventricles/pathology , Heart Ventricles/physiopathology , Humans , Male , Oxygen Consumption , Predictive Value of Tests , Pulmonary Atresia/complications , Pulmonary Atresia/diagnosis , Pulmonary Atresia/physiopathology , Pulmonary Circulation , Severity of Illness Index , Treatment Outcome , Ventricular Dysfunction, Right/etiology , Ventricular Dysfunction, Right/physiopathology , Young Adult
3.
Lupus ; 19(3): 330-3, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19897521

ABSTRACT

Patients with systemic lupus erythematosus (SLE) are susceptible to the development of lymphoproliferative disorders and postulated causes include intrinsic defects in immune surveillance and iatrogenic administration of immunosuppressants. Since the introduction of mycophenolate mofetil (MMF) to the immunosuppressive regimen for the management of post-organ transplantation, there have been reports of primary lymphoma of the central nervous system (PCNSL). MMF has been widely used to treat active SLE patients with Class IV lupus nephritis. In addition to two previously reported cases of PCNSL among SLE patients on long-term MMF, we report a third patient who has been on treatment with MMF for 8 years. The histology showed features compatible with diffuse large B-cell lymphoma with strong immunohistochemical staining for CD20 and positive signal for Epstein-Barr virus (EBV)-encoded RNA by in-situ hybridization that is similar to other case reports, suggesting EBV driven B-cell lymphoproliferative disease. The patient responded to withdrawal of MMF, intravenous methotrexate, rituximab and whole brain radiotherapy. With the increasing use of MMF in active renal as well as non-renal exacerbations of SLE, PCNSL should be included in the differential diagnosis in patients who present with gradual onset of focal neurological deficit.


Subject(s)
Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Lymphoma, Large B-Cell, Diffuse/therapy , Mycophenolic Acid/analogs & derivatives , Adult , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Murine-Derived , Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Agents/therapeutic use , Central Nervous System Neoplasms/etiology , Central Nervous System Neoplasms/therapy , Central Nervous System Neoplasms/virology , Epstein-Barr Virus Infections/complications , Female , Humans , Immunosuppressive Agents/adverse effects , Lymphoma, Large B-Cell, Diffuse/etiology , Lymphoma, Large B-Cell, Diffuse/virology , Methotrexate/therapeutic use , Mycophenolic Acid/adverse effects , Mycophenolic Acid/therapeutic use , Rituximab
SELECTION OF CITATIONS
SEARCH DETAIL
...